-
Fosun Pharma to Hike Aitrox Stake to 72.63% for USD 61M
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) plans to increase its ownership of Aitrox from 28.23% to 72.63% in a deal valued at RMB 412.35 million (USD 61 million). The investment includes a direct capital injection of RMB 50 million (USD 7.4 million) and the acquisition of…
-
GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline
•
GluBio Pharmaceutical Co., Ltd, a Zhejiang-based specialist in molecular glue targeted protein degradation (TPD), reportedly raised USD 22 million in a Series A+ financing round. The round brings the company’s total funding to USD 90 million since its founding in March 2023. Existing investor Qiming Venture Partners led the round,…
-
BridGene Biosciences Completes USD 38.5M Series B Round with China Funds
•
U.S.-based biotech BridGene Biosciences Inc. has completed a Series B financing round, raising USD 38.5 million. The round was backed by China-based funds, including Beijing’s Lapam Capital, Hong Kong’s Junson Capital, and Xiamen’s Dyee Capital. Funding UseProceeds will support the development of BridGene’s proprietary chemoproteomic platform IMTAC, including clinical trials…
-
Basecare Medical Sells 35% Stake in Cellpro Biotech for USD 9.5M
•
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based IVF specialist, will sell a 35% stake in its assisted reproductive product developer Zhejiang Cellpro Biotech Co., Ltd for RMB 64.17 million (USD 9.5 million). Post-deal, Basecare will retain a 15% stake in Cellpro, having previously acquired 51% of the firm…
-
Sanjin Pharma’s Subsidiary Gets FDA Nod for BC007 Cancer Drug Trial
•
China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Pharmaceutical (Shanghai) Co., Ltd, has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I clinical study of BC007, a bispecific antibody (BsAb) targeting CLDN18.2 and CD47, in patients with solid…
-
Pica Partners with BrainCo to Launch ADHD Product in China
•
Shanghai-based primary healthcare digital platform Pica, developed by Wuxi AppTec in 2016, has partnered with BrainCo, a firm operating in China and the U.S., to launch the latter’s ADHD product in China. Financial details of the deal were not disclosed. Product DetailsThe ADHD product features a smart, non-invasive brain-computer interface…
-
NHC Designates National Mental Illness Medical Centers in Beijing and Shanghai
•
The National Healthcare Commission (NHC) announced the establishment of national mental illness medical centers, designating Peking University Sixth Hospital and Beijing Anding Hospital of Capital Medical University as joint main bodies. Shanghai Mental Health Center and the Second Xiangya Hospital of Central South University will also establish separate national mental…
